Home › Buying a business › Pharmacy
Written for pharmacy buyers
Buying a pharmacy, where an earnings error gets multiplied.
Written by Priyank Thakkar: finance broker, former bank commercial credit assessor, active property developer.
Written for pharmacists buying their first or next pharmacy, and the accountants and lawyers alongside them.
A pharmacy sits behind a regulatory moat: controlled locations, PBS approval, profit above the retail average. That protection is real. It is also why the risks in a pharmacy deal sit somewhere unfamiliar, and why the price is a multiple. Every dollar you fail to adjust out of the earnings gets multiplied three to five times over.
Subject to lender criteria, security position and eligibility. Figures on this page reviewed quarterly, last reviewed August 2026. Next review: November 2026.
30 minutes with Priyank, former bank lending manager and commercial credit analyst, member of the Australian Institute of Business Brokers.
Download the 5-page guide (PDF) → No email required.
The industry, in four numbers
A bigger, more defensible business than most retail. Priced accordingly.
About $29.9 billion of revenue across 4,305 pharmacies: roughly $6.9 million each, with around 21 staff. Industry profit of $1.7 billion works out near $395,000 per pharmacy before the owner’s own wage. Margin sits at 5.7%, down slightly over five years.
| Measure | Industry | What it means for your deal |
|---|---|---|
| Pharmacies | 4,305 | A controlled number. Location rules limit where a new one can open, which is the moat. |
| Revenue each | ~$6.9m | Turnover is large. It is not the number that prices the business. |
| Profit each, before the owner’s wage | ~$395,000 | This is what gets rebuilt, then multiplied. Get it wrong and the error multiplies too. |
| Margin | 5.7% | Above general retail, and compressing. The direction matters more than the level. |
Published Australian industry research current to August 2026. General information only, not a valuation and not advice about any particular business.
The amplification
Get the earnings wrong by $230,000 and at a 4x multiple you have got the price wrong by $920,000. In a café the same error costs you thirty thousand dollars. That single difference is why the rebuild has to happen before you offer, not after.
Two businesses, one shopfront
Almost every listing prices them as one number.
Dispensary revenue sits behind location rules and PBS approval, a genuine moat, but the remuneration structure has been cut repeatedly by reform: a defensible position with a shrinking margin. Front of store competes with supermarkets, online retailers and discount chains, with no protection at all, and it is also where pharmacies are being told to grow. Both things are true at once.
| Revenue stream | Share | Risk profile |
|---|---|---|
| Prescription medicines | 66.1% | Protected by location rules and PBS approval. Margin under structural pressure from reform. |
| General retail | 24% | Fully exposed to supermarkets, discounters and online. Also the nominated growth path. |
| Scheduled non-prescription | 7.1% | Pharmacy-only, but price-comparable and increasingly shopped around. |
| Professional services | 2.8% | Small today. Scope of practice is expanding, and this is where the sector is being pushed. |
Ask for the split before you assume anything. A pharmacy that is 80% dispensary is a regulated annuity under margin pressure. One that is 60% dispensary with a strong front of store and real professional services is a different asset, and worth a different multiple. Two risk profiles, two growth paths, one asking price.
The rebuild
What the lender assesses, against what the listing advertises.
Australian pharmacies typically trade around 3 to 5 times EBITDA, or roughly 1.0 to 1.5 times annual gross profit, moving with location, lease and recent trading. Because the price is a multiple, the rebuild is the whole negotiation.
| The rebuild | Amount | Why it moves |
|---|---|---|
| PEBITDA as advertised | $520,000 | The number the listing leads with, before the owner’s own wage comes out. |
| A managing pharmacist at market rate | − $155,000 | Someone registered has to run it. If that is you, it is a salary, not a return. |
| Second-pharmacist hours the owner covers | − $45,000 | Weekend and overlap cover that is currently unpaid because the owner does it. |
| Rent under the lease you will sign | − $18,000 | The accounts carry the old rent. You will not. |
| Fit-out or systems due inside 24 months | − $12,000 | Dispensing software, robotics or a refit already at end of life. |
| What the lender assesses | $290,000 | At 4x, a price of $2.08m on the advertised figure against $1.16m on the assessed one. The business has not changed. Only your understanding of it has. |
Illustrative only, to show the shape of the adjustment. Not a valuation and not a representation about any particular business. General information only, current at August 2026.
Stock is normally bought at valuation on top of the price, and in a pharmacy that is not a rounding item. Ask early how stock is counted, when, and who pays for what is out of date.
The timing question
Do the financials you have been shown span 60-day dispensing?
Sixty-day dispensing commenced on 1 September 2023 and now covers around 300 medicines. For eligible medicines a patient collects two months’ supply in one visit, which means fewer dispensing occasions, fewer dispensing fees, and fewer trips into the shop. Industry estimates at the time pointed to a 15 to 25% reduction in script volumes for affected medicines, and the reduced foot traffic flows through to front-of-store sales as well.
So it is a timing question, not an opinion
If the three years you are shown begin before September 2023, part of that history describes a business that no longer exists. If they begin after it, you are seeing the reset, which is what you are actually buying. Ask which, and get monthly figures either side of the change if they exist.
This is the single most common way a pharmacy is priced on earnings that cannot repeat. It is also the easiest to check: one question, asked before you spend money on due diligence.
Two structural questions
Which pole is it on, and how old is the catchment?
Which pole
The industry has polarised into two viable positions: small, high-service pharmacies offering clinical and preventative health services, and large, high-volume, low-margin pharmacies competing on price. Following the Chemist Warehouse and Sigma merger in early 2025, winning on price as a single-owner operator became materially harder.
So the most dangerous pharmacy to buy is the one in the middle: not low-priced enough to win on price, not clinical enough to win on service. Work out which pole it sits on before you value it. If the answer is neither, that is the finding.
How old is the catchment
Pharmaceutical consumption rises steeply with age. Australians aged 60 and over account for more than 60% of all dispensed PBS-subsidised medicines. People under 40, more than half the population, account for less than 15%.
The age profile of the catchment is close to a direct revenue predictor, and it is publicly available. A pharmacy beside a retirement precinct and one beside a university are entirely different assets with the same shopfront. Pull the census profile for the suburb, look at what is being built nearby, and ask what the catchment looks like in ten years.
And the question underneath both
Where do the scripts actually come from? If a co-located or neighbouring medical centre generates most of the dispensary volume, then that centre’s lease, its doctors and its succession plan are part of your due diligence, because if the doctors leave, the scripts leave with them.
The funding
Funding is decided on the submission, not only the deal.
Pharmacy is a sector most lenders have a formed view about, and several have dedicated appetite for. What is achievable turns on the rebuilt earnings, the lease and options against the loan term, whether the premises come with it, the ownership structure, and how the dispensary and front-of-store split is presented. Presented well, a pharmacy is one of the more fundable business acquisitions in the market.
Get your capacity assessed first
Before you negotiate, not after. You learn your real ceiling, and you negotiate like someone who can settle. Deposit workings are set out on our business deposit guide.
The lease sets the loan
Lenders generally want the lease, options included, to run at least as long as the facility. Ask for the term and the options in the first conversation. It screens out sites before you fall for them.
Structure before contract
Ownership of a pharmacy is restricted, and the entity you buy through affects tax, succession and lending. Settle the structure with your accountant and lawyer before you sign, not between contract and settlement.
Subject to lender criteria, security position and eligibility. We arrange credit; we do not provide legal, tax or accounting advice, and pharmacy ownership rules vary between states and territories.
Nine questions, two minutes. Then a call within four business hours. No application, and no credit enquiry.
Fair questions
Straight answers.
How much does it cost to buy a pharmacy in Australia?
It varies widely with location, script volume and lease, but the pricing convention is consistent: roughly 3 to 5 times EBITDA, or about 1.0 to 1.5 times annual gross profit, with stock bought at valuation on top. On industry-average economics a pharmacy turns over about $6.9 million and earns near $395,000 before the owner’s wage, so transactions commonly land in the seven-figure range. The number that matters is not the asking price but the rebuilt earnings it is a multiple of.
How are pharmacies valued in Australia?
On a multiple of earnings, which is why the earnings figure has to be rebuilt first. Typically 3 to 5 times EBITDA, or 1.0 to 1.5 times annual gross profit, moving with location, lease and recent trading. Because it is a multiple, an unadjusted $230,000 of owner’s wages inside the advertised figure becomes a $920,000 pricing error at 4 times. Rebuild the number before you offer.
How did 60-day dispensing change what a pharmacy is worth?
Sixty-day dispensing commenced on 1 September 2023 and covers around 300 medicines. Eligible patients collect two months’ supply in one visit, so there are fewer dispensing occasions, fewer fees and fewer visits to the shop. Industry estimates at the time pointed to a 15 to 25% fall in script volumes for affected medicines, with knock-on effects on front-of-store sales. Practically, it means financials that begin before September 2023 describe a business that no longer exists in the same form. Ask whether the figures you have been shown span the change.
Do you have to be a pharmacist to own a pharmacy in Australia?
In general yes. Ownership of community pharmacies is restricted to registered pharmacists across Australia, with limits on how many a pharmacist may hold and some long-standing exceptions such as friendly societies. The detail differs between states and territories, and the structure you buy through matters for both approval and lending. Confirm the position for your state with a lawyer experienced in pharmacy transactions before you sign anything.
Can you get finance to buy a pharmacy?
Yes, and pharmacy is a sector several lenders actively support. What is achievable depends on the rebuilt earnings, the lease and option terms against the loan term, the security position, whether the premises are included, and the ownership structure. Get your borrowing capacity assessed before you negotiate rather than after. Subject to lender criteria, security position and eligibility.
What should you check before buying a pharmacy?
Five things ahead of the rest. Whether the financials span 60-day dispensing. The split between dispensary, front of store and professional services. Which pole the pharmacy sits on, high-service or high-volume, and whether it is stranded in the middle. The age profile of the catchment, which is publicly available and close to a direct revenue predictor. And where the scripts actually originate, because a neighbouring medical centre’s doctors and lease can be the real asset you are buying.
The 5-page guide covers the dispensary and front-of-store split, 60-day dispensing, location rules and PBS approval, ownership restrictions, stock at valuation, and the 12 deal-killers. Download it here → No email required.